Business Standard

Monday, December 23, 2024 | 10:50 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Merck expects strong growth from India, says executive board member

The life science division which manufactures laboratory materials, chemicals and is the largest of its segment in India

Udit Batra, member of the Merck Executive Board and CEO, Life Science
Premium

Udit Batra, member of the Merck Executive Board and CEO, Life Science

Aneesh Phadnis Mumbai
Merck is increasing its investment in India and introducing products and solutions to support biosimilar manufacturing in the country, Udit Batra, executive board member of the 350-year-old German pharmaceutical and chemical maker said on Thursday.

“We expect strong growth from India. We are ready to bring bioproduction technology in India in a meaningful way. We have already done that successfully in other countries,” said Delhi-born Batra who heads the company's life science division.

While Merck plans to introduce new anti-cancer drugs in India, the main growth driver for its business in India will come from sale of products and services

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in